Ester-E(R) linked to healthy cardiovascular function- study

24/10/05 Zila, Inc. has commented on a study conducted for the Australian company, Phosphagenics Limited, that confirms an earlier study suggesting that Ester-E(R) may proactively benefit cardiovascular health. In this animal study, Ester-E(R) significantly reduced LDL-C (so-called bad cholesterol), triglycerides, and plaque formation, while regular vitamin E had no significant effect.

Zila Nutraceuticals, Inc., a wholly owned subsidiary of Zila, Inc., has an exclusive license to the patented Phosphagenics vitamin E technology within the dietary supplement category and currently produces and distributes Ester-E(R) in the United States.

The study data showed that this unique form of vitamin E lowered bad cholesterol concentrations in blood by up to 44% and triglycerides by up to 51% in mice fed normal diets. When fed high cholesterol diets, Ester-E(R) significantly reduced plaque formation in the aorta by 58%. Again, regular vitamin E had no significant effect on plaque formation. These results confirm the earlier animal study indicating that Ester-E(R) may have the potential to yield healthier levels of total cholesterol, triglycerides and LDL-C in humans. The animal model chosen for the trials is commonly used in cardiovascular research as it mimics many of the properties observed clinically in humans.

Ester-E(R) is the registered trademark of Zila Nutraceuticals, Inc. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051020005460&newsLang=en